The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II open-label study of cabozantinib after first-line treatment including an immune-checkpoint combination in patients with advanced or unresectable renal cell carcinoma: The BREAKPOINT trial (MeetUro trial 03 - EudraCT number 2018-000582-36).
 
Giuseppe Procopio
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pfizer
 
Chiara Pircher
No Relationships to Disclose
 
Melanie Claps
No Relationships to Disclose
 
Valentina Guadalupi
No Relationships to Disclose
 
Alessia Mennitto
No Relationships to Disclose
 
Pierangela Sepe
No Relationships to Disclose
 
Francesca Corti
No Relationships to Disclose
 
Ugo De Giorgi
No Relationships to Disclose
 
Cristian Lolli
No Relationships to Disclose
 
Umberto Basso
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen-Cilag; MSD
Research Funding - Ipsen
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Janssen-Cilag; Novartis; Pfizer; Sanofi
Other Relationship - Astellas Pharma; Bristol-Myers Squibb; Janssen-Cilag; Novartis; Sanofi/Aventis
 
Marco Maruzzo
No Relationships to Disclose
 
Davide Bimbatti
No Relationships to Disclose
 
Elena Verri
No Relationships to Disclose
 
Franco Nole
No Relationships to Disclose
 
Sandro Pignata
Honoraria - AstraZeneca; MSD; pfizer; pharmamar; Roche; Tesaro
Consulting or Advisory Role - AstraZeneca; Pfizer; PharmaMar; Roche; tesaro
Research Funding - AstraZeneca (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
 
Filippo G. De Braud
Honoraria - Bristol-Myers Squibb; Merck; MSD; Pfizer; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb; EMD SERONO; Ignyta; Incyte; Nerviano Medical Sciences; Octimet; Pierre Fabre; Roche; Sanofi; Teofarma
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Roche (Inst); SERVIER (Inst); Tesaro (Inst)
 
Elena Verzoni
Consulting or Advisory Role - Janssen Oncology; Pfizer
Speakers' Bureau - Ipsen; Novartis